The six / BPC-157
BPC-157
Also: Body Protection Compound 157, pentadecapeptide BPC
The most searched peptide in the group, with the longest animal record and the thinnest human one.
Class
Synthetic pentadecapeptide, 15 amino acids
Sequence
GEPPPGKPADDAGLV
Origin
Fragment modelled on a protective protein in human gastric juice; Zagreb, 1989 to 1992
Policy form
BPC-157 acetate
Permitted routes
Subcutaneous, intramuscular, oral, topical
Human evidence
Limited: no completed randomised trial
What people ask for it for
Tendon, ligament and muscle injury, recovery after procedures and training, and gut complaints. It is the peptide people who train, and people recovering from procedures, ask about by name.
What the policy allows
BPC-157 acetate. Subcutaneous, intramuscular, oral and topical. Oral forms need documented human bioavailability for the specific formulation.
Strength of the evidence
LimitedHundreds of animal papers, most from one research group. A 2025 systematic review of 544 articles found one human clinical study that met its criteria. No randomised controlled trial has been completed.
Where it comes from
BPC-157 is a 15-amino-acid fragment modelled on a larger protective protein found in human gastric juice. The idea dates to the mid-1970s; the peptide was isolated in 1989 by a team led by Predrag Sikiric at the University of Zagreb and first published in 1992.
The Croatian pharmaceutical company PLIVA developed it from 1993, for a time with Parke-Davis. GlaxoSmithKline acquired PLIVA's research institute in 2006, shelved the programme, and the rights went back to Sikiric in 2009. From then on BPC-157 lived as a research chemical rather than a drug candidate, which is how it reached gyms and podcasts.
Sikiric has published more than 150 papers on it, and most of the roughly 200 BPC-157 entries on PubMed have him or a close colleague as an author. Reviewers outside that group point this out, not as an accusation but because independent replication is what the field lacks.
How it is thought to work
From cell and animal models unless stated
In cell and animal models BPC-157 promotes angiogenesis, the growth of new blood vessels, mainly through the VEGFR2-Akt-eNOS pathway, and interacts with the nitric oxide system that governs blood flow.
It increases collagen production and activates fibroblasts, the cells that lay down connective tissue, and in tendon cells it raises expression of the growth hormone receptor.
It reduces inflammatory signalling in several models and has effects on pain pathways. It does not appear to act through a single, well-defined receptor, which is why it is described as cytoprotective, a broad label rather than a mechanism.
In animals it is metabolised by the liver and cleared by the kidney with a half-life under thirty minutes. Human pharmacokinetics have not been published.
What the research shows
Study by study, labelled by what it was. The third column is the citation; the full references are at the foot of the page.
In cells and animals
Rat Achilles tendon, transected
The most replicated finding. Treated tendons were stronger and more elastic, and the defect had shrunk by day 14.
PubMed 14554208
Muscle, ligament and bone injury in rodents
Faster healing across several models, most from the Zagreb group.
Cell and Tissue Research review, 2019
Gastrointestinal tissue
Mucosal protection and healing, the emphasis of the earliest work and the reason it was called a body protection compound.
Sikiric et al., Pharmaceuticals
Systematic review of the musculoskeletal literature
Of 36 included studies, 35 were preclinical. The authors concluded human evidence is inadequate to support clinical recommendations.
Vasireddi et al., 2025; PMC12446177
In people
Two ulcerative colitis trials, PLIVA era, early 2000s
Small, enema route. The second reported a positive trend that did not reach significance. No resulting papers appear in PubMed.
STAT News, 2026
Oral tablet Phase 1 safety study, Tijuana, around 2015
Registered as NCT02637284. Status unknown, no results posted, no publication. Sikiric's 2025 review says it found the drug safe, without data.
ClinicalTrials.gov
Knee pain case series, single injection, 12 patients
Seven reported relief lasting over six months. No control group, no effect size, no safety data.
Alternative Therapies in Health and Medicine
Intravenous infusion pilot, two healthy adults, 2025
No measurable change in cardiac, liver, kidney or thyroid markers and no reported side effects. Two people, no control, no efficacy endpoint.
Lee and Burgess, 2025; PubMed 40131143
Safety, and what is not known
- There is no established human safety profile. The few human reports are tiny, uncontrolled and from one group, so the honest statement is that side effects cannot be described as rare or mild; they are undescribed.
- FDA's 2023 concerns were that BPC-157 could trigger an immune response, that products may contain peptide-related impurities, and that safety information is incomplete. The HHS policy answers the sourcing and impurity points with its testing and certificate requirements; it does not answer the immunogenicity question.
- A theoretical concern raised by independent reviewers: a substance that grows new blood vessels could in principle feed a tumour. No case has been reported, and no study has looked.
- Online user reports mention whole-body itch, anxiety and low mood. Causation is unknown, product identity in those reports is unknown, and the dosing people describe is often far above anything studied.
- Oral use is permitted by the policy only with documentation that the specific formulation is absorbed in humans. Most peptides are not, so an oral product without that documentation is outside the policy.
What the HHS policy says about BPC-157
BPC-157 acetate
Subcutaneous, intramuscular, oral and topical. Oral forms need documented human bioavailability for the specific formulation.
- Appendix B records that historical use is now documented, that lot-specific certificates of analysis from FDA-registered manufacturers exist, and that the remaining risk is managed through lot testing, single-ingredient products and MedWatch reporting.
- The free base was previously listed alongside the acetate; the policy's permitted form is the acetate.
- BPC-157 may not be combined with TB-500 or anything else in one product. A clinician can prescribe two separate products if appropriate.
All ten conditions of the policy →
Sport
Prohibited at all times under S0, non-approved substances. If you compete in tested sport, know this before you start.
Regulatory status
-
Never
FDA approval. No application for approval of this substance has been filed in the US, and no trial exists that could support one.
-
September 2023
Placed in Category 2 of FDA's interim 503A bulk substances list, the category for substances where FDA identified significant safety risks. Reputable pharmacies stopped compounding it.
-
April 2026
Removed from the active Category 2 table after the Federal Register notice announcing advisory committee review.
-
July 2026
Pharmacy Compounding Advisory Committee recommended it for the 503A bulks list on July 23, by 8 votes to 6 with one abstention. FDA's own briefing had concluded the evidence was insufficient.
-
October 28, 2026
Covered by the HHS enforcement discretion policy. Compoundable by state-licensed pharmacies and physicians that meet all ten of the policy's conditions, for an individual patient on a valid prescription. Still not on the 503A bulks list and still not approved.
Getting BPC-157 through Healthy Peptides
You complete a health intake. An independent clinician at Beluga Health reviews it and decides whether BPC-157 is appropriate for you, and by which permitted route. If prescribed, a state-licensed pharmacy that meets every condition of the HHS policy compounds the single-ingredient product and ships it to you. Healthy Peptides sells you the program; Local Healthcare bills you as its agent.
What we will and will not tell you
- WillWhat the research on BPC-157 actually shows, graded honestly, and the routes a pharmacy may prepare.
- WillWho made it, who prescribed it, who billed you, and how to report a problem.
- Will notCall BPC-157 approved, proven, safe or natural, or promise a result.
- Will notPublish a dose or protocol. That is between you, the clinician and the pharmacy label.
Questions about BPC-157
Is BPC-157 legal now?
Since October 28, 2026 a state-licensed pharmacy or physician may compound BPC-157 acetate for an individual patient on a prescription, provided every condition of the HHS enforcement discretion policy is met. It is not FDA-approved, it is not on the 503A bulks list, and a vial sold online without a prescription is as unlawful as it was before.
Does BPC-157 work?
In rats, tendons and gut tissue heal faster with it, and that finding has been repeated many times. In people, nobody knows. There is no completed randomised trial, the human reports are tiny and uncontrolled, and the reviewers who have looked hardest say the evidence cannot support a clinical recommendation yet.
Can it be taken by mouth?
The policy permits an oral form only where the pharmacy can document that the specific formulation achieves adequate bioavailability in humans. Without that documentation an oral product is outside the policy. Injection and topical forms do not carry that condition.
Is it safe?
Unknown. Animal studies report few problems, two healthy adults tolerated an intravenous infusion, and that is the published human safety record. FDA's stated concerns in 2023 were immunogenicity, impurities and missing data. The policy addresses impurities through testing; the rest remains open.
Can my staff talk about it?
They can say the program exists and that a clinician decides. They cannot say what it does, suggest it for an injury, or discuss dose or route. On a substance with this evidence base, a healing claim from your front desk is both a regulatory problem and a promise nobody can keep.
BPC-157 is not FDA-approved and no clinical trial has established that it is safe or effective for any use. The research described on this page is reported as what it is, cell, animal or small human studies, and is not a benefit you should expect. Programs are provided only where an independent, licensed clinician determines they are clinically appropriate after reviewing your health history, and not everyone qualifies. Compounded BPC-157 is prepared by a state-licensed pharmacy under a patient-specific prescription and the conditions of the HHS enforcement discretion policy of October 28, 2026, which is not an approval and may be withdrawn. Availability varies by state. This page is general information, not medical advice. Last reviewed October 29, 2026.
Sources
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. 2025
- Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. 2025
- Lee E, Burgess A. Safety of intravenous infusion of BPC157 in humans: a pilot study. 2025
- STAT News: BPC-157, the peptide with big claims and scant evidence (February 2026)
- Superpower peptide guide: BPC-157 (sourced summary of the literature)
- ClinicalTrials.gov NCT02637284
- HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B (October 28, 2026)
- AJMC: FDA panel backs 6 peptides for compounding (July 2026)
- FDA: Bulk drug substances used in compounding under section 503A
- WADA: 2026 Prohibited List